您好,欢迎进入未来科学出版社官网!

用科学铸就未来,用阅读滋养人生

Use science to create the future, and use reading to nourish life

+65 6396 6190

客服服务时间:9:00-18:00

当前位置: 首页 >> 英文期刊 >> Modern General Practice >> 2024 >> 1

Treatment of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease with Yiqi Huoxue Powder: A Study on Cognition, Daily Living Abilities, and HDS-R Scores

作者:Zhong Dayong; Yang Yan; Dong Mingli; Tang Banghua; Wu Yuanqiang; Jiang Zheng; Cai Zekun; Chen Jun; Hu Hongyu

院校:Sichuan Third Veterans' Hospital; Sichuan Famous Traditional Chinese Medicine Doctor Zhong Dayong Studio

摘要:Objective To investigate the efficacy of Yiqi Huoxue Powder in treating patients with MCI due to Alzheimer's Disease (AD) in terms of cognition, daily living abilities, and HDS-R scores. Methods A total of 98 patients with MCI due to AD, admitted from August 2023 to August 2024, were randomly divided into an observation group and a control group, with 49 patients in each. The control group received Almitrine Bismylate and Rauwolfia Serpentina Tablet treatment, while the observation group received Yiqi Huoxue Powder in addition to the control group’s treatment. The treatment period was 4 weeks per course, for a total of 3 courses. Changes in cognition, daily living abilities, and HDS-R scores, as well as clinical efficacy, were observed before and after treatment in both groups. Results The total effective rate in the observation group was 96.8%, significantly higher than the 76.5% in the control group, with a statistically significant difference (P < 0.05). After treatment, the observation group showed significantly higher scores in cognition, daily living abilities, and HDS-R compared to the control group, with statistically significant differences (P < 0.05). Conclusion Yiqi Huoxue Powder demonstrates significant efficacy in treating MCI due to AD, significantly improving patients’ cognition, daily living abilities, and HDS-R scores.

关键词

MCI due to Alzheimer's Disease; Yiqi Huoxue Powder; Cognitive Function

全文

PDF

参考

[1] Jia L, Du Y, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a crosssectional study[J]. Lancet Public Health, 2020, 5(12): e661e671.DOI: 10.1016/s2468-2667(20)30185-7.
[2] Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease[J]. Alzheimers Dement, 2018, 14(4): 535-562.DOI: 10.1016/j.jalz.2018.02.018.
[3] Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease[J]. Nat Rev Dis Primers, 2021, 7(1): 33. DOI:10.1038/s41572-021-00269-y.
[4] LESZEK J, SOCHOCKA M, GĄSIOROWSKI K. Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer’s disease[J]. Journal of the Neurological Sciences, 2012, 323(1/2): 25-32.
[5] the Journal of Alzheimer’s Disease and Related Disorders. Pages 175-192, Issue 3, 2023.
[6] Alzheimer’s Association International Conference. Revised criteria for diagnosis and staging of Alzheimer’s disease:Alzheimer’s Association Workgroup [EB/OL].[2023-10-25]. https://aaic.alz.org/nia-aa.asp#workgroup.
[7] WinbladB, PalmerK, KivipeltoM, et al. Mild cognitive impairment -- beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment[J]. J Intern Med, 2004, 256( 3): 240- 246. DOI: 10.1111/j.1365-2796.2004.01380.x.

+65 6396 6190

微信二维码